TWEAK induces osteoclastogenesis in vitro and in vivo [26], indicating that anti-TWEAK-based therapeutics may inhibit bone resorption and degradation observed in RA and more importantly, may also augment the efficacy of other RA therapeutics with non-overlapping modes of action. The gene discussed is TNFSF12; the disease is rheumatoid arthritis.